# US 2019/0314488 A1 · Materials and methods for respiratory disease control in canines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314488 A1
- Document ID: US20190314488A1
- Status: Published application
- Kind: A1
- Application number: 16/382,429
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2005-04-21
- Assignees: University of Florida Research Foundation, Inc.; Cornell Research Foundation, Inc.; The Government of U.S.A. as represented by the Secretary of the Department of Health and Human Servi
- Applicants: University of Florida Research Foundation, Inc.; Cornell Research Foundation, Inc.; The Government of U.S.A. as represented by the Secretary of the Department of Health and Human Servi
- Inventors: PATTI CYNTHIA CRAWFORD; PAUL J. GIBBS; EDWARD J. DUBOVI; RUBEN OMAR DONIS; JACQUELINE KATZ; ALEXANDER I. KLIMOV; NALLAKANNU P. LAKSHMANAN; MELISSA ANNE LUM; DANIEL GHISLENA EMIEL GOOVAERTS; MARK WILLIAM MELLENCAMP; NANCY J. COX; WILLIAM L. CASTLEMAN
- Web page: https://patentgrep.com/patent/US20190314488A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12Q 1/701: {Specific hybridization probes}
- G01N 33/56983: {Viruses}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- C12N 2710/24043: viral genome or elements thereof as genetic vector
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16171: Demonstrated in vivo effect
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.

## Claims

### Claim 1

An isolated influenza virus that is capable of infecting a canid animal.

### Claim 2 (depends on 1)

A reassortant virus comprising at least one gene, genomic segment, or a polynucleotide of an influenza virus of claim 1.

### Claim 3 (depends on 2)

The reassortant virus according to claim 2, wherein said reassortant virus is formulated in a pharmaceutically acceptable carrier or diluent.

### Claim 4

An isolated virus that comprises one or more polynucleotides wherein said one or more polynucleotides encode a canine influenza virus protein selected from the group consisting of HA, NA, NP, MA, PB1, PB2, PA, and NS, or a functional or immunogenic fragment thereof.

### Claim 5 (depends on 4)

The virus according to claim 4, wherein said one or more polynucleotides comprise a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77.

### Claim 6 (depends on 4)

The virus according to claim 4, wherein said HA protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 62, and 78.

### Claim 7 (depends on 4)

The virus according to claim 4, wherein said NA protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 58, and 74.

### Claim 8 (depends on 4)

The virus according to claim 4, wherein said NP protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 56, and 72.

### Claim 9 (depends on 4)

The virus according to claim 4, wherein said MA protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 60, and 76.

### Claim 10 (depends on 4)

The virus according to claim 4, wherein said PB1 protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 50, and 66.

### Claim 11 (depends on 4)

The virus according to claim 4, wherein said PB2 protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 48, and 64.

### Claim 12 (depends on 4)

The virus according to claim 4, wherein said PA protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 52, and 68.

### Claim 13 (depends on 4)

The virus according to claim 4, wherein said NS protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 54, and 70.

### Claim 14 (depends on 4)

The virus according to claim 4, wherein said virus is provided in a pharmaceutically acceptable carrier or diluent.